Please assess the completion status of the following clinical trial:

Trial Title: Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed Consent as documented by signature~2. Subjects (males and females) age ≥ 18 years~3. ECOG \< 3~4. Subjects with pyrexia grade 1\*- 4 and elevated CRP with persistent fever after one day of antipyretic therapy with or without at least one other additional symptom of cytokine release syndrome such as nausea, headache, tachycardia, hypotension, maculopapular rash, shortness of breath, transaminitis, renal failure, dehydration~5. Elevated CRP serum levels further than normal baseline levels (\> 3.0 mg/L)~6. Subjects with resected, non-resectable, adjuvant or metastatic BRAF+ melanoma treated with :~   * BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib)~  * BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib) preceded by therapy with anti-PD-1/PD-L1 and/or anti CTLA-4 inhibitor~  * BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib) plus anti-PD- 1/PD-L1 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: OTHER): The patients will be administered Tocilizmab (Actemra) at the following dosage :~* First dose: 8mg/kg, max. 800mg iv. during 60min~* If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose

Based on this trial design, predict the completion outcome and termination type (if applicable).